ST段抬高型心肌梗死直接PCI患者P2Y12抑制剂给药时机
该研究基于前瞻性多中心注册数据,评估ST段抬高型心肌梗死(STEMI)转运行直接PCI患者P2Y12抑制剂预处理的安全性与有效性。结果显示预处理与30天主要不良心脏事件(MACE)风险降低相关(校正HR 0.53),未增加出血风险,且获益呈时间依赖性,仅在给药至PCI间隔超过80分钟时显现。
要点
- P2Y12抑制剂预处理与30天MACE风险降低相关,校正HR 0.53(95%CI 0.37-0.76)。
- 预处理未显著增加大出血风险,校正HR 0.62(95%CI 0.36-1.05)。
- 预处理获益呈时间依赖性,仅在给药至PCI间隔超过80分钟时显现。
核心结论
- 在转运行直接PCI的当代STEMI患者中,P2Y12抑制剂预处理与30天MACE显著时间依赖性降低相关,且不增加出血风险。
研究设计与样本
- 基于前瞻性多中心注册数据的分析,纳入1624例转运行直接PCI的STEMI患者。
- 预处理定义为冠状造影前给予P2Y12抑制剂;采用基于倾向评分的双稳健加权估计模型分析结局关联。
主要发现
- 1033例在造影前接受P2Y12抑制剂,591例在导管室接受。
- 预处理组校正后MACE风险更低(校正HR 0.53;95%CI 0.37-0.76),大出血风险未显著增加(校正HR 0.62;95%CI 0.36-1.05),净临床获益更优(校正HR 0.47;95%CI 0.26-0.86)。
- MACE风险存在显著的治疗-by-时间交互作用,预处理获益仅在给药至PCI间隔超过80分钟时显现。
临床怎么用
- 对于转运行直接PCI且预计给药至PCI间隔可能超过80分钟的STEMI患者,可考虑造影前给予P2Y12抑制剂预处理以降低30天MACE风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal timing of P2Y12 inhibitor administration in patients with ST-segment elevation myocardial infarction (STEMI) has not been completely elucidating. OBJECTIVES: This analysis from a prospective multicenter registry sought to assess the safety and effectiveness of P2Y12 inhibitor pretreatment in patients transferred for primary percutaneous coronary intervention (PCI) within a regional STEMI network. METHODS: Pretreatment was defined as P2Y12 inhibitor administration before coronary angiography. Endpoints were major adverse cardiac events (MACE), major bleeding, and net adverse clinical events, a composite of MACE or major bleeding, within 30 days of index admission. Association of P2Y12 inhibitor pretreatment with outcomes was modeled using doubly robust weighted estimators based on propensity score analysis. RESULTS: Of 1,624 patients included, 1,033 received P2Y12 inhibitors before angiography and 591 in the catheterization laboratory (cath lab). The non-pretreated cohort more often had history of coronary artery disease and were more likely to receive antiplatelet therapy before the index admission. After adjustment for confounding and dependent censoring, pretreatment with P2Y12 inhibitors predicted lower risk of MACE (adjusted HR: 0.53; 95% CI: 0.37-0.76), without increasing bleeding risk (adjusted HR: 0.62; 95% CI: 0.36-1.05), resulting in superior net clinical benefit (adjusted HR: 0.47; 95% CI: 0.26-0.86) compared with in-cath lab administration of P2Y12 inhibitors. There was a significant treatment-by-time interaction for MACE risk, whereby the observed benefits of pretreatment only became apparent when time between P2Y12 inhibitor administration and PCI was longer than 80 minutes. CONCLUSIONS: In contemporary patients with STEMI transferred for primary PCI, pretreatment with P2Y12 inhibitors was associated with a significant time-dependent reduction of 30-day MACE without increasing bleeding risk.
引用
- Almendro-Delia M, Hernández-Meneses B, Padilla-Rodríguez G, et al. Timing of P2Y12 Inhibitor Administration in Patients With STEMI Undergoing Primary PCI. J Am Coll Cardiol. 2024. PMID: 38897672. doi:10.1016/j.jacc.2024.04.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。